18.81
+1.865(+11.01%)
Currency In USD
| Previous Close | 16.95 |
| Open | 16.31 |
| Day High | 18.97 |
| Day Low | 16.31 |
| 52-Week High | 34.27 |
| 52-Week Low | 3.6 |
| Volume | 119,537 |
| Average Volume | 246,728 |
| Market Cap | 139.31M |
| PE | -1.21 |
| EPS | -15.54 |
| Moving Average 50 Days | 20.1 |
| Moving Average 200 Days | 12.14 |
| Change | 1.87 |
If you invested $1000 in Scilex Holding Company (SCLX) since IPO date, it would be worth $54.56 as of November 09, 2025 at a share price of $18.81. Whereas If you bought $1000 worth of Scilex Holding Company (SCLX) shares 3 years ago, it would be worth $53.74 as of November 09, 2025 at a share price of $18.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI
GlobeNewswire Inc.
Nov 03, 2025 2:53 PM GMT
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management product
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
GlobeNewswire Inc.
Oct 01, 2025 1:00 PM GMT
PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management product
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
GlobeNewswire Inc.
Sep 26, 2025 7:57 PM GMT
PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management produ